Structure of BMS-986143, a potent, reversible inhibitor of the Bruton's tyrosine kinase (BTK)

oral reversible selective BTK kinase inhibitor

related cmpds in dev. for inflamm. conditions

from rational design of prior crystallized leads

ACS Med. Chem. Lett., Sep. 22, 2020

Bristol Myers Squibb, Princeton, NJ

BMS-986143 is a potent, reversible inhibitor of the Bruton’s tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible drugs for oncology. The safety bar is much…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.